gene in patients relapsing after remedy Together with the BCL2 antagonist venetoclax. 66 Resistance to these agents has been connected to these mutations in all over 70% of scenarios, Whilst they are usually subclonal as well as their specific role causing resistance needs to be proven. ??? "